-
Je něco špatně v tomto záznamu ?
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
JA. Cohen, G. Comi, KW. Selmaj, A. Bar-Or, DL. Arnold, L. Steinman, HP. Hartung, X. Montalban, E. Kubala Havrdová, BAC. Cree, JK. Sheffield, N. Minton, K. Raghupathi, V. Huang, L. Kappos, RADIANCE Trial Investigators,
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 2002-05-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2002-05-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2002-05-01 do Před 2 měsíci
Psychology Database (ProQuest)
od 2002-05-01 do Před 2 měsíci
- MeSH
- bradykardie chemicky indukované MeSH
- dospělí MeSH
- imunosupresiva škodlivé účinky terapeutické užití MeSH
- indany aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- infekce etiologie MeSH
- interferon beta 1a škodlivé účinky terapeutické užití MeSH
- lékové postižení jater etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mozek patologie MeSH
- následné studie MeSH
- neurozobrazování MeSH
- oxadiazoly aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- progrese nemoci MeSH
- receptory sfingosin-1-fosfátu antagonisté a inhibitory MeSH
- relabující-remitující roztroušená skleróza farmakoterapie patologie MeSH
- šedá hmota patologie MeSH
- stupeň závažnosti nemoci MeSH
- velikost orgánu MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
BACKGROUND: Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI measures and was well tolerated. The RADIANCE phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis. METHODS: We did a 24-month, multicentre, double-blind, double-dummy phase 3 trial in participants with relapsing multiple sclerosis at 147 medical centres and clinical practices in 21 countries. Participants were aged 18-55 years, had multiple sclerosis according to 2010 McDonald criteria, a relapsing clinical course, brain MRI lesions consistent with multiple sclerosis, an expanded disability status scale score of 0·0-5·0, and either at least one relapse within 12 months before screening or at least one relapse within 24 months before screening plus at least one gadolinium-enhancing lesion within the 12 months before randomisation. Participants were randomly assigned (1:1:1) via an interactive voice response system to daily oral ozanimod 1·0 mg or 0·5 mg or weekly intramuscular interferon beta-1a 30 μg. Participants, investigators, and study staff were masked to treatment allocation. The primary endpoint was annualised relapse rate (ARR) over 24 months. The primary analysis was done in the intention-to-treat population of all participants who received study drug and safety was assessed in all randomly assigned participants who received study drug, grouped by highest dose of ozanimod received. This trial is registered at ClinicalTrials.gov, NCT02047734, and EudraCT, 2012-002714-40. FINDINGS: Between Dec 27, 2013, and March 31, 2015, we screened 1695 participants, of which 375 did not meet inclusion criteria. 1320 participants were enrolled and randomly assigned to a group, of whom 1313 received study drug (433 assigned to ozanimod 1·0 mg, 439 assigned to ozanimod 0·5 mg, and 441 assigned to interferon beta-1a) and 1138 (86·7%) completed 24 months of treatment. Adjusted ARRs were 0·17 (95% CI 0·14-0·21) with ozanimod 1·0 mg, 0·22 (0·18-0·26) with ozanimod 0·5 mg, and 0·28 (0·23-0·32) with interferon beta-1a, with rate ratios versus interferon beta-1a of 0·62 (95% CI 0·51-0·77; p<0·0001) for ozanimod 1·0 mg and 0·79 (0·65 to 0·96; p=0·0167) for ozanimod 0·5 mg. The incidence of treatment-emergent adverse events was higher in the interferon beta-1a group (365 [83·0%] of 440 participants) than in the ozanimod 1·0 mg group (324 [74·7%] of 434) or the ozanimod 0·5 mg group (326 [74·3%] of 439). More participants in the interferon beta-1a group had treatment-emergent adverse events leading to treatment discontinuation than in the ozanimod groups. Incidences of infections and serious treatment-emergent adverse events were similar across treatment groups. No cases of ozanimod-related symptomatic reduction in heart rate and no second-degree or third-degree cases of atrioventricular block were reported. INTERPRETATION: In this 24-month phase 3 study in participants with relapsing multiple sclerosis, ozanimod was well tolerated and associated with a significantly lower rate of clinical relapses than intramuscular interferon beta-1a. These findings show the potential of ozanimod as an effective oral therapy for individuals with relapsing multiple sclerosis. FUNDING: Celgene International II.
Center for Neurology Lodz Poland
Collegium Medicum Department of Neurology University of Warmia and Mazury Olsztyn Poland
Department of Biostatistics Celgene Corporation Summit NJ USA
Department of Clinical Development Celgene Corporation Summit NJ USA
Department of Neurology Medical Faculty Heinrich Heine University Dusseldorf Germany
Division of Neurology St Michael's Hospital University of Toronto Toronto ON Canada
Drug Safety Celgene Corporation Summit NJ USA
Mellen Center for Multiple Sclerosis Treatment and Research Cleveland Clinic Cleveland OH USA
Neurologic Clinic and Policlinic University Hospital and University of Basel Basel Switzerland
NeuroRx Research and Montréal Neurological Institute McGill University Montreal QC Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023541
- 003
- CZ-PrNML
- 005
- 20201214130334.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1474-4422(19)30238-8 $2 doi
- 035 __
- $a (PubMed)31492652
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Cohen, Jeffrey A $u Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA. Electronic address: cohenj@ccf.org.
- 245 10
- $a Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial / $c JA. Cohen, G. Comi, KW. Selmaj, A. Bar-Or, DL. Arnold, L. Steinman, HP. Hartung, X. Montalban, E. Kubala Havrdová, BAC. Cree, JK. Sheffield, N. Minton, K. Raghupathi, V. Huang, L. Kappos, RADIANCE Trial Investigators,
- 520 9_
- $a BACKGROUND: Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI measures and was well tolerated. The RADIANCE phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis. METHODS: We did a 24-month, multicentre, double-blind, double-dummy phase 3 trial in participants with relapsing multiple sclerosis at 147 medical centres and clinical practices in 21 countries. Participants were aged 18-55 years, had multiple sclerosis according to 2010 McDonald criteria, a relapsing clinical course, brain MRI lesions consistent with multiple sclerosis, an expanded disability status scale score of 0·0-5·0, and either at least one relapse within 12 months before screening or at least one relapse within 24 months before screening plus at least one gadolinium-enhancing lesion within the 12 months before randomisation. Participants were randomly assigned (1:1:1) via an interactive voice response system to daily oral ozanimod 1·0 mg or 0·5 mg or weekly intramuscular interferon beta-1a 30 μg. Participants, investigators, and study staff were masked to treatment allocation. The primary endpoint was annualised relapse rate (ARR) over 24 months. The primary analysis was done in the intention-to-treat population of all participants who received study drug and safety was assessed in all randomly assigned participants who received study drug, grouped by highest dose of ozanimod received. This trial is registered at ClinicalTrials.gov, NCT02047734, and EudraCT, 2012-002714-40. FINDINGS: Between Dec 27, 2013, and March 31, 2015, we screened 1695 participants, of which 375 did not meet inclusion criteria. 1320 participants were enrolled and randomly assigned to a group, of whom 1313 received study drug (433 assigned to ozanimod 1·0 mg, 439 assigned to ozanimod 0·5 mg, and 441 assigned to interferon beta-1a) and 1138 (86·7%) completed 24 months of treatment. Adjusted ARRs were 0·17 (95% CI 0·14-0·21) with ozanimod 1·0 mg, 0·22 (0·18-0·26) with ozanimod 0·5 mg, and 0·28 (0·23-0·32) with interferon beta-1a, with rate ratios versus interferon beta-1a of 0·62 (95% CI 0·51-0·77; p<0·0001) for ozanimod 1·0 mg and 0·79 (0·65 to 0·96; p=0·0167) for ozanimod 0·5 mg. The incidence of treatment-emergent adverse events was higher in the interferon beta-1a group (365 [83·0%] of 440 participants) than in the ozanimod 1·0 mg group (324 [74·7%] of 434) or the ozanimod 0·5 mg group (326 [74·3%] of 439). More participants in the interferon beta-1a group had treatment-emergent adverse events leading to treatment discontinuation than in the ozanimod groups. Incidences of infections and serious treatment-emergent adverse events were similar across treatment groups. No cases of ozanimod-related symptomatic reduction in heart rate and no second-degree or third-degree cases of atrioventricular block were reported. INTERPRETATION: In this 24-month phase 3 study in participants with relapsing multiple sclerosis, ozanimod was well tolerated and associated with a significantly lower rate of clinical relapses than intramuscular interferon beta-1a. These findings show the potential of ozanimod as an effective oral therapy for individuals with relapsing multiple sclerosis. FUNDING: Celgene International II.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a bradykardie $x chemicky indukované $7 D001919
- 650 _2
- $a mozek $x patologie $7 D001921
- 650 _2
- $a lékové postižení jater $x etiologie $7 D056486
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a šedá hmota $x patologie $7 D066128
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x škodlivé účinky $x terapeutické užití $7 D007166
- 650 _2
- $a indany $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007189
- 650 _2
- $a infekce $x etiologie $7 D007239
- 650 _2
- $a interferon beta 1a $x škodlivé účinky $x terapeutické užití $7 D000068556
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $x patologie $7 D020529
- 650 _2
- $a neurozobrazování $7 D059906
- 650 _2
- $a velikost orgánu $7 D009929
- 650 _2
- $a oxadiazoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D010069
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a receptory sfingosin-1-fosfátu $x antagonisté a inhibitory $7 D000081025
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Comi, Giancarlo $u Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
- 700 1_
- $a Selmaj, Krzysztof W $u Center for Neurology, Lodz, Poland; Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland.
- 700 1_
- $a Bar-Or, Amit $u Center for Neuroinflammation and Experimental Therapeutics, and Multiple Sclerosis Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- 700 1_
- $a Arnold, Douglas L $u NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada.
- 700 1_
- $a Steinman, Lawrence $u Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA.
- 700 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany.
- 700 1_
- $a Montalban, Xavier $u Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada; Department of Neurology-Neuroimmunology, and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a Kubala Havrdová, Eva $u Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic.
- 700 1_
- $a Cree, Bruce A C $u Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
- 700 1_
- $a Sheffield, James K $u Department of Clinical Development, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Minton, Neil $u Drug Safety, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Raghupathi, Kartik $u Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Huang, Vivian $u Department of Biostatistics, Celgene Corporation, Summit, NJ, USA.
- 700 1_
- $a Kappos, Ludwig $u Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland.
- 710 2_
- $a RADIANCE Trial Investigators
- 773 0_
- $w MED00006921 $t The Lancet. Neurology $x 1474-4465 $g Roč. 18, č. 11 (2019), s. 1021-1033
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31492652 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130333 $b ABA008
- 999 __
- $a ok $b bmc $g 1595860 $s 1114217
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 18 $c 11 $d 1021-1033 $e 20190903 $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921
- LZP __
- $a Pubmed-20201125
